Fred Berendsen

Commercieel directeur at MICREOS - Den Haag, Zuid Holla, NL

Fred Berendsen's Colleagues at MICREOS
Josephine Krouwel

Senior Customer Care representative Gladskin

Contact Josephine Krouwel

Benthe Freyee

Clinical Project Manager

Contact Benthe Freyee

Jan Sonsma

Quality Assurance Officer

Contact Jan Sonsma

Roy Andries

Head of Business Services

Contact Roy Andries

View All Fred Berendsen's Colleagues
Fred Berendsen's Contact Details
HQ
N/A
Location
The Hague,South Holland,Netherlands
Company
MICREOS
Fred Berendsen's Company Details
MICREOS logo, MICREOS contact details

MICREOS

Den Haag, Zuid Holla, NL • 100 - 249 Employees
BioTech/Drugs

According to the World Health Organization (WHO) emergence of antibiotic-resistant 'superbugs' is now a global concern, which can spell the end of modern medicine and a return to the days when routine operations, simple wounds or straightforward infections were potentially life-threatening. On the other hand scientists have come to realize that the vast majority of bacteria is beneficial and should be left intact. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance. Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria - including antibiotic resistant strains such as MRSA - while leaving our microbiome - comprising billions of beneficial bacteria on our skin and in our gut - intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us: killing the bad bacteria and preserving the microbiome. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections (see www.gladskin.com). A series of pharmaceutical products based on the endolysin XZ.700 - also targeting S. aureus - is in clinical development. First indications include: atopic dermatitis, diabetic wound infections and folliculitis. Micreos has also developed FDA-approved food safety products: 'Phageguard S' against Salmonella and 'Phageguard L' against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised (www.phageguard.com).

Research & Development Product introduction World class phage production Contract manufacturing Phage Technology Endolysin Technology Phage production Endolysin Production Microbiome Staphylococcus aureus MRSA Human Health Dermatology Eczema Rosacea Acne Folliculitis Diabetic Wound Infections Food Safety Listeria Salmonella Intracellular Staph Phageguard Gladskin
Details about MICREOS
Frequently Asked Questions about Fred Berendsen
Fred Berendsen currently works for MICREOS.
Fred Berendsen's role at MICREOS is Commercieel directeur.
Fred Berendsen's email address is ***@micreos.com. To view Fred Berendsen's full email address, please signup to ConnectPlex.
Fred Berendsen works in the Research industry.
Fred Berendsen's colleagues at MICREOS are Steven Hagens, Josephine Krouwel, Thomas Wade, Benthe Freyee, Jan Sonsma, Mark Offerhaus, Roy Andries and others.
Fred Berendsen's phone number is N/A
See more information about Fred Berendsen